Cargando…

PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

Detalles Bibliográficos
Autores principales: Daver, N. G., Wei, A. H., Stein, E. M., DeAngelo, D. J., Pathak, D., Xu, Y., Grzesiak, S., Venditti, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429529/
http://dx.doi.org/10.1097/01.HS9.0000850248.63603.48
_version_ 1784779472296214528
author Daver, N. G.
Wei, A. H.
Stein, E. M.
DeAngelo, D. J.
Pathak, D.
Xu, Y.
Grzesiak, S.
Venditti, A.
author_facet Daver, N. G.
Wei, A. H.
Stein, E. M.
DeAngelo, D. J.
Pathak, D.
Xu, Y.
Grzesiak, S.
Venditti, A.
author_sort Daver, N. G.
collection PubMed
description
format Online
Article
Text
id pubmed-9429529
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94295292022-08-31 PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY Daver, N. G. Wei, A. H. Stein, E. M. DeAngelo, D. J. Pathak, D. Xu, Y. Grzesiak, S. Venditti, A. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429529/ http://dx.doi.org/10.1097/01.HS9.0000850248.63603.48 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Daver, N. G.
Wei, A. H.
Stein, E. M.
DeAngelo, D. J.
Pathak, D.
Xu, Y.
Grzesiak, S.
Venditti, A.
PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
title PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
title_full PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
title_fullStr PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
title_full_unstemmed PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
title_short PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
title_sort pb1849: trial in progress: phase ib/ii study of siremadlin in combination with venetoclax + azacitidine in patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429529/
http://dx.doi.org/10.1097/01.HS9.0000850248.63603.48
work_keys_str_mv AT daverng pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy
AT weiah pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy
AT steinem pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy
AT deangelodj pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy
AT pathakd pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy
AT xuy pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy
AT grzesiaks pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy
AT vendittia pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy